Empagliflozin attenuates arrhythmogenesis in diabetic cardiomyopathy by normalizing intracellular Ca<sup>2+</sup> handling in ventricular cardiomyocytes
Takahide Kadosaka, Masaya Watanabe, Hiroyuki Natsui, Takuya Koizumi, Motoki Nakao, Taro Koya, Hikaru Hagiwara, Rui Kamada, Taro Temma, Fuyuki Karube, Fumino Fujiyama, Toshihisa Anzai
Abstract
SGLT2is are known to improve cardiovascular outcomes regardless of the presence of diabetes and decrease traditional cardiovascular risk factors. We demonstrated, for the first time, that EMPA inhibited PVCs by normalizing Ca 2+ handling in diabetic mice. Our data suggest that the effects of SGLT2is on calcium handling may occur because of suppression of O-GlcNAcylation through inhibition of glucose uptake and not because of NHE inhibition, as previously suggested.
Topics & Concepts
EmpagliflozinInternal medicineDiabetic cardiomyopathyEndocrinologyEMPAMedicineDiastoleCardiomyopathyDiabetes mellitusCardiologyHeart failureChemistryType 2 diabetesBlood pressureMineralogyElectron microprobeDiabetes Treatment and ManagementPancreatic function and diabetesCardiovascular Function and Risk Factors